https://european-biotechnology.net/wp-content/uploads/2026/05/anirudh-djo3iNJpaOE-unsplash-1030x589-1.jpg5891030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-05-07 08:00:162026-05-07 08:00:16Scarlet raises £3.2 million to advance lab-grown red blood cell therapies
https://european-biotechnology.net/wp-content/uploads/2026/05/Seite-26_macrocycle-example-orbismed.jpg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-05-06 12:00:122026-05-06 12:00:12Macrocycles: big is the new beautiful
https://european-biotechnology.net/wp-content/uploads/2026/02/getty-images-lqoCCWZpRY0-unsplash-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-05-05 11:57:032026-05-05 11:57:03Swiss Windward Bio adds US$165m to its Chinese pipeline
https://european-biotechnology.net/wp-content/uploads/2026/05/resource-database-GWktL2yRXtA-unsplash-1030x824-1.jpg8241030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-05-05 07:00:152026-05-05 07:00:15Cytospire raises £61M to take gamma-delta T-cell engager into the clinic
https://european-biotechnology.net/wp-content/uploads/2026/05/virginia-marinova-2TQ0QnC-cA0-unsplash-1030x773-1.jpg7731030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-05-04 16:51:272026-05-04 16:51:27UCB buys Candid Therapeutics for up to US$2.2bn to deepen autoimmune T-cell engager push
https://european-biotechnology.net/wp-content/uploads/2026/04/planet-volumes-HCK8YihP47Y-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-30 12:29:382026-04-30 12:29:38BioOrbit: record seed round for in‑space drug manufacturing
https://european-biotechnology.net/wp-content/uploads/2026/04/20260430-valneva-financing-1030x579-1.png5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-30 06:22:552026-04-30 06:22:55Valneva reels in €84m in fresh financing to shore up vaccine pipeline
